1 ASX stock to consider buying that could be the next ResMed

There are obviously no guarantees in the share market. But if you're willing to take on some risk, the rewards could be great in 10 years' time.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Resmed CDI (ASX: RMD) has been a staple in many ASX stock portfolios for decades now.

And it has rewarded the faith handsomely, becoming a 6-bagger over the past ten years. 

It's a stunning 19-bagger if you go back 20 years.

Of course, the catch is that those investors who bought in March 2004 or 2014 would not have known with 100% certainty that their investment would become so successful.

That's the nature of investing in shares. You buy them when they're cheaper to take on the risk that the story could turn sour — or become a wild triumph.

There is one ASX stock at the moment that I think has the potential to become the next ResMed.

While I can't tell you whether it will have become a 6-bagger in 2034, it currently has a fighting chance to be much higher compared to now.

This ASX stock has tripled in a year

Like ResMed, Clarity Pharmaceuticals Ltd (ASX: CU6) also plays in the healthcare field but is involved in developing products for prostate cancer.

Already this year the stock price has rocketed just shy of 30%. The shares have more than tripled in the past year.

That's all due to favourable results coming from testing of its copper therapies on prostate cancer patients.

Back in January, Frazis Capital portfolio manager Michael Frazis was full of praise for the Sydney biotech.

"This is the most exciting company I've come across in Australia lately."

Providing hope for a bleak situation

Even though prostate cancer is common, the fact remains treatments can be soul-destroying for patients.

"Treatment involves radical prostatectomy to remove 'the true heart of the male', hormone therapy, and traditional radiotherapy and chemotherapy," said Frazis in a memo to clients.

"These come with a bleak list of side effects: incontinence, impotence, loss of interest in sex, and depression."

Clarity is one of a bunch of companies seeking to improve this situation.

"The hope is that the next generation of radiopharmaceuticals will be able to differentiate between harmless and metastatic disease, limit unnecessary treatments, catch any recurrence, and ultimately cure prostate cancer without such bleak side effects."

Admittedly the $717 million company is sparsely covered by professional investors at the moment.

But broking platform CMC Invest shows at least Jefferies and Wilsons rating Clarity Pharmaceuticals as a buy currently.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 5 December 2024

Motley Fool contributor Tony Yoo has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »